PROTEIMER Trademark

Biopharmaceutical preparations for the treatment of cancer and neurological and neurodegenerative diseases; therapeutic proteins, namely, targeted binding proteins engineered for high-affinity and specificity to disease-associated targets, for use in modulating cellular signaling pathways and disease progression; biologic preparations for the treatment of oncological, neurological, metabolic, and immunological disorders; aptamer-based therapeutic agents for targeted treatment of cancer, including immune cell engagers that recruit and activate immune effector cells, including T cells and natural killer (NK) cells, against tumor cells, and for targeted delivery of therapeutic payloads, including cytotoxic agents, nucleic acids, and protein therapeutics, to specific human tissues; protein-based drug candidates, namely, multi-specific and modular biopharmaceutical preparations for the treatment of cancer and neurological and neurodegenerative diseases; antibody mimetics being engineered proteins for targeted modulation of disease pathways, selective receptor agonism or antagonism, blood-brain barrier penetration, and delivery of therapeutic agents to human tissue

Scientific and technological research and design in the fields of biotechnology, pharmaceutical development, research and development of protein-based therapeutics, aptamer-based drug discovery platforms, biologic drug delivery systems, and biologically active molecules for therapeutic use; providing information in the field of scientific research and design in biotechnology